慢性乙型肝炎患者的乙型肝炎表面抗原损失 慢性乙型肝炎患者的低病毒载荷
Tyng-Yuan Jang1,2,3, Batbold Batsaikhan4, Yo-Chia Chen5
1PhD Program of Environmental and Occupational Medicine and Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Journal of gastroenterology and hepatology
|July 20, 2024
概括
年龄较小和先前的核酸/核酸模拟剂 (NA) 治疗与慢性乙型肝炎患者的乙型肝炎表面抗原 (HBsAg) 损失有关. 目前的NA治疗显示与HBsAg损失有负相关性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 乙型肝炎病毒 (HBV) 感染是一个全球性的健康问题.
- 乙型肝炎表面抗原 (HBsAg) 的丢失意味着慢性乙型肝炎 (CHB) 的功能治愈.
- 在低HBVDNA水平的患者中影响HBsAg损失的因素尚不清楚.
研究的目的:
- 确定与低病毒载荷 (HBV DNA <2000 IU/mL) 的CHB患者的HBsAg损失相关的因素.
- 调查先前和当前核酸/核酸类似物 (NA) 治疗在实现HBsAg损失中的作用.
主要方法:
- 80名CHB患者的回顾性研究,病毒载量低,HBeAg阴性.
- 根据随访期间的HBsAg损失来对患者进行分类.
- 使用后勤回归分析来确定与HBsAg损失相关的因素.
主要成果:
- 在21.3%的患者中发生HBsAg损失.
- 获得HBsAg损失的患者年轻 (平均年龄为57.9岁相比65.5岁),HBV DNA水平较低.
- 之前的NA治疗史 (OR:7.59) 和年龄<60岁 (OR:3.95) 与HBsAg损失有关.
- 目前的NA治疗与HBsAg损失负相关 (OR:0.19).
结论:
- 年轻的年龄和先前的NA治疗史是低病毒载荷CHB患者HBsAg损失的有利因素.
- 目前的NA疗法可能不会直接促进HBsAg损失,但一些患者在治疗期间会达到这一点.
- 需要进一步的研究来优化对HBsAg损失和功能治愈的策略.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Hepatitis
80
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
80
Viral Hepatitis I: Introduction
22
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
22


